- Home
- LGND vs KYMR Comparison
LGND vs KYMR Comparison
Compare LGND & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGND
- KYMR
- Stock Information
- Founded
- LGND 1987
- KYMR 2015
- Country
- LGND United States
- KYMR United States
- Employees
- LGND N/A
- KYMR N/A
- Industry
- LGND Biotechnology: Pharmaceutical Preparations
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- LGND Health Care
- KYMR Health Care
- Exchange
- LGND Nasdaq
- KYMR Nasdaq
- Market Cap
- LGND 2.0B
- KYMR 1.8B
- IPO Year
- LGND 1992
- KYMR 2020
- Fundamental
- Price
- LGND $114.07
- KYMR $45.87
- Analyst Decision
- LGND Strong Buy
- KYMR Strong Buy
- Analyst Count
- LGND 8
- KYMR 16
- Target Price
- LGND $144.71
- KYMR $59.38
- AVG Volume (30 Days)
- LGND 116.0K
- KYMR 1.1M
- Earning Date
- LGND 08-05-2025
- KYMR 08-06-2025
- Dividend Yield
- LGND N/A
- KYMR N/A
- EPS Growth
- LGND N/A
- KYMR N/A
- EPS
- LGND N/A
- KYMR N/A
- Revenue
- LGND $181,488,000.00
- KYMR $58,885,000.00
- Revenue This Year
- LGND $18.41
- KYMR $43.38
- Revenue Next Year
- LGND $18.87
- KYMR $10.97
- P/E Ratio
- LGND N/A
- KYMR N/A
- Revenue Growth
- LGND 53.40
- KYMR N/A
- 52 Week Low
- LGND $77.53
- KYMR $19.45
- 52 Week High
- LGND $129.90
- KYMR $53.27
- Technical
- Relative Strength Index (RSI)
- LGND 62.44
- KYMR 67.58
- Support Level
- LGND $111.88
- KYMR $45.80
- Resistance Level
- LGND $116.16
- KYMR $47.51
- Average True Range (ATR)
- LGND 3.58
- KYMR 2.86
- MACD
- LGND 0.89
- KYMR -0.03
- Stochastic Oscillator
- LGND 85.19
- KYMR 67.19
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.